Psychosomatic and Psychological Impact of Hepatitis C: A Cross-Sectional Study of Depression, Fibrosis, and Somatic Symptoms in Treatment-Naive and Treatment-Experienced Patients Who Achieved Sustained Virologic Response

丙型肝炎的身心影响:一项横断面研究,探讨了初治患者和经治患者在获得持续病毒学应答后出现的抑郁、纤维化和躯体症状。

阅读:1

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection is associated with neuropsychiatric symptoms, including depression and psychosomatic complaints. While direct-acting antivirals (DAAs) have revolutionized HCV treatment, their impact on mental health and systemic symptoms remains unclear. This study aimed to compare depression severity, liver fibrosis scores, and psychosomatic symptoms in treatment-naive (Tx-naive) and treatment-experienced (Tx-experienced) patients who achieved sustained virologic response (SVR). MATERIALS AND METHODS: A cross-sectional observational study was conducted at two tertiary care hospitals in Pakistan. Patients with chronic HCV were categorized into Tx-naive and Tx-experienced SVR-achieved groups. Depression was assessed using the Patient Health Questionnaire-9 (PHQ-9), while fibrosis severity was determined using Fibrosis-4 (FIB-4) scores. Psychosomatic symptoms, including myalgia, asthenia, and functional dyspepsia, were documented. Statistical comparisons were performed using independent t-tests, Mann-Whitney U tests, and Chi-squared tests. RESULTS: A total of 142 patients were analyzed, with 69 in the Tx-naive group and 73 in the Tx-experienced SVR-achieved group. PHQ-9 scores did not significantly differ between groups (p=0.343) or FIB-4 scores (p=0.691). The prevalence of psychosomatic symptoms was comparable across both cohorts, with no statistically significant differences in individual symptoms such as asthenia, myalgia, or burning feet syndrome (all p>0.05). CONCLUSIONS: The findings suggest that HCV itself, rather than DAA therapy, is the primary contributor to depression and somatic symptoms. Achieving SVR does not significantly alter mental health or systemic symptom burden. These results highlight the need for long-term neuropsychiatric monitoring in HCV survivors, as symptoms may persist despite viral clearance. Future research should explore the biological underpinnings of these persistent complaints and assess potential interventions for improving patient quality of life.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。